Breaking News, Collaborations & Alliances

GRIN Therapeutics, Angelini Pharma Partner to Develop & Commercialize Radiprodil

Collaboration combines Angelini Pharma’s global reach and focus on complex neurological disorders with GRIN’s expertise and capabilities in developing and advancing precision therapeutics for neurodevelopmental disorders.

Author Image

By: Charlie Sternberg

Associate Editor

GRIN Therapeutics Inc., a developer of therapies to treat serious neurodevelopmental disorders, and Angelini Pharma, part of the privately owned Angelini Industries, have partnered for the development and commercial rights outside of North America of GRIN Therapeutics’ investigational drug radiprodil, currently being studied in multiple rare genetic epilepsies and neurodevelopmental disorders. GRIN Therapeutics also announced the closing of its $140 million Series D financing with investment ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters